Inclusion Criteria:  Voluntary participation and informed consent, aged 18-75; Patients with HCC confirmed by histopathology or meeting the clinical diagnostic criteria in the 2019 edition of the diagnostic and therapeutic criteria for primary liver cancer; BCLC stage C patients with vascular invasion and without extrahepatic metastasis; Child Pugh liver function classification: A or B grade; ECOG physical strength score was 0-2 points; No previous systemic or local treatment, and the expected survival time is more than 3 months; According to recist1.1, the patient must have at least one measurable target lesion that has passed CT or MRI examination, and the tumor imaging evaluation was conducted within 2 weeks before receiving the study drug; Full organ and bone marrow function: WBC ≥ 3.0 × 109/L； NE≥1.5 × 109/L； PLT≥75 × 109/L； Liver and kidney function ALT and AST ≤ 5uln; TBIL≤2ULN； Albumin ≥ 28g / L; Cr≤1.5 ULN； International normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) exceeding the normal control range ≤ 4 seconds;  Exclusion Criteria:  Hepatocholangiocarcinoma, mixed cell carcinoma and fibrolamellar cell carcinoma are known; Uncontrollable ascites, hepatic encephalopathy or esophageal variceal bleeding; Patients with hypertension who can not be reduced to normal range after antihypertensive drug treatment (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); Patients with myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmia, myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmia (QTc interval ≥ 450 ms) (QTc interval was calculated by fridericia formula); Patients with history of gastrointestinal bleeding or definite tendency of gastrointestinal bleeding in the past 3 months, such as esophageal varices with bleeding risk, local active ulcer lesions, fecal occult blood ≥ +, can not be included in the group; Pregnant or lactating women, patients with fertility are unwilling or unable to take effective contraceptive measures; patients with a history of HIV infection; The researcher judges other situations that may affect the clinical research and the judgment of research results;